A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • STATUS
    Recruiting
Updated on 14 December 2020
Investigator
Incyte Corporation Call Center
Primary Contact
Keio University Hospital (8.8 mi away) Contact
+61 other location
cancer
measurable disease
FGFR1
metastasis
primary tumor
solid tumors
primary cancer
solid tumor
FGFR2
malignancy
FGFR3
administration intravenous
malignancies

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

 

Description

  • Interventional Study
  • Estimated Enrollment:170 participants
  • Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations.
  • This study consists of 3 cohorts that will have study drug administered in parallel, Cohort A, Cohort B, and Cohort C.
  • There is no difference in the treatment regimen between the cohorts.

Details
Condition Solid Tumors, Advanced Malignancies
Clinical Study IdentifierTX233266
Last Modified on14 December 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply
Age 18 years or older, inclusive at the time of signing the informed consent
Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic (Stage IIIB or IV per the AJCC Cancer Staging Manual, 6th ed; AJCC 2002) or is surgically unresectable
Radiographically measurable disease (per RECIST v1.1 or RANO for primary brain tumors). Tumor lesions located in a previously irradiated area, or in an area subjected to other loco-regional therapy, are considered measureable if progression has been clearly demonstrated in the lesion
Documentation of an FGFR1-3 gene mutation or translocation (Section 8.5.1 and Appendix C). Participants will be assigned to 1 of 3 cohorts
Cohort A: FGFR1-3 in-frame fusions or FGFR2 intron 17 rearrangements
Cohort B: Known/predicted activating point mutations in FGFR1-3 (excluding kinase domain, see Appendix C)
Cohort C: Any FGFR1-3 point mutations in the kinase domain or FGFR1/FGFR3 rearrangements with unknown partners and variants of unknown significance not included in Appendix C
Must have objective progression after at least 1 prior therapy, and must have no therapy available that is likely to provide clinical benefit. Participants who are intolerant to or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit
ECOG performance status 0 to 2
Baseline archival tumor specimen (if less than 12 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis
Willingness to avoid pregnancy or fathering children based on the criteria below
Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug(s)/treatment and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed
Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose on Day 1 and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed
Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea) are eligible
Table 9
ary Laboratory Values
Laboratory Parameter

Exclusion Criteria

Table 9: Exclusionary Laboratory Values
Laboratory Parameter Exclusion Criterion
Hematology
a Platelets ≤ 75 × 109/L (transfusion allowed with 2-week washout period)
b Hemoglobin ≤ 9.0 g/L (transfusion allowed within 2-week washout period)
c ANC ≤ 1.5 × 109/L
Hepatic
e ALT ≥ 3 × ULN (> 5 × ULN for liver metastasis)
f AST ≥ 3 × ULN (> 5 × ULN for liver metastasis)
g Total bilirubin ≥ 1.5 × ULN (≥ 2.5 × ULN if Gilbert’s syndrome or liver metastasis)
h Alkaline phosphatase ≥ 3 × ULN
Renal
i Serum creatinine clearance ≤ 30 mL/minute based on Cockcroft-Gault formula
Chemistry
j Serum phosphate > ULN
k Serum calcium Outside of normal range or serum albumin-corrected calcium outside of the normal range when serum albumin is outside of the normal range
History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessels due to injury, disease, or aging in the absence of systemic mineral imbalance)
Gastrointestinal condition/disorders that may raise gastric and/or small intestinal pH that could interfere with absorption, metabolism, or excretion of pemigatinib
Inability to swallow and retain oral medication
Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug/treatment administration, New York Heart Association Class III or IV congestive heart failure, and uncontrolled arrhythmia (participants with pacemaker or with atrial fibrillation and well controlled heart rate are allowed)
History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. A screening QTcF interval > 480 ms is excluded. For participants with an intraventricular conduction delay (QRS interval > 120 ms), the JTc interval may be used in place of the QTc with medical monitor approval. The JTc must be ≤ 340 ms if JTc is used in place of the QTc
Active chronic or current infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment within 2 weeks before enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed)
Evidence of active HBV or HCV infection (defined as participants with elevated transaminases or cirrhosis. Participants with chronic HBV/HCV infection with no cirrhosis and no elevated transaminases are allowed)
Known HIV infection
Current use of prohibited medication as described in Section 6.6.2
Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or five half lives (whichever is longer) before the first dose of study drug/treatment. Note that moderate CYP3A4 inhibitors are not prohibited
Known hypersensitivity or severe reaction to pemigatinib or excipients of pemigatinib (refer to the IB)
Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator
Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy
Women who are pregnant or breastfeeding
Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug/treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data
Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend the ICF or unwillingness to sign the ICF
History of hypovitaminosis D requiring supraphysiologic doses (eg, 50,000 UI/weekly) to replenish the deficiency. Vitamin D supplements are allowed
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note